Skip to Content

Join the 'Cobicistat' group to help and get support from people like you.

Cobicistat News

HIV Infection Seems to Affect Nervous System

Posted 13 Jun 2016 by Drugs.com

MONDAY, June 13, 2016 – Many newly infected HIV patients experience neurological problems, but they tend to be mild and they subside after antiretroviral drugs are given, a new study finds. "We were surprised that neurologic findings were so pervasive in participants diagnosed with very recent HIV infection," said study author Dr. Joanna Hellmuth. She is a clinical fellow in the department of ...

HIV Can Persist in Body Despite Drug Therapy

Posted 27 Jan 2016 by Drugs.com

WEDNESDAY, Jan. 27, 2016 – Even when blood tests of HIV patients on antiretroviral drugs show no sign of the AIDS-causing virus, it can still be replicating in lymphoid tissue, researchers report. The study offers important new insight into how HIV persists in the body despite treatment with the powerful drugs, according to the team of international researchers led by Northwestern University's ...

Drug Makers, Governments Sign Deal to Fight Drug-Resistant Infections

Posted 21 Jan 2016 by Drugs.com

A groundbreaking agreement between the drug industry and governments to work together to fight drug-resistant "superbugs" is expected to be announced Thursday. Under the deal, 74 drug makers, 11 diagnostic test makers, and nine industry groups pledge to work with each other and 16 countries to prevent and improve treatment of drug-resistant infections, the Associated Press reported. These ...

FDA Approves Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) for HIV

Posted 5 Nov 2015 by Drugs.com

The U.S. Food and Drug Administration today approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older. The CDC estimates that 1.2 million persons ages 13 years and older are living with HIV infection, and that ...

HIV Therapy May Also Lower Risk for Hepatitis B, Study Says

Posted 12 Oct 2015 by Drugs.com

MONDAY, Oct. 12, 2015 – Not only does effective HIV therapy thwart the AIDS-causing virus, it may also reduce the risk for hepatitis B infection, a new study says. "What this means to us is that effective HIV therapy appears to restore an impairment in the immune response that protects someone with HIV from acquiring hepatitis B infection," study senior author Dr. Chloe Thio, a professor of ...

Many U.S. AIDS Patients Still Die When 'Opportunistic' Infections Strike

Posted 1 Jul 2015 by Drugs.com

WEDNESDAY, July 1, 2015 – Even after the advent of powerful medications for suppressing HIV, a new study finds that more than one-third of people in San Francisco who were diagnosed with an AIDS-related infection died within five years. "The main cause of mortality arises from people stopping treatment entirely," said Dr. Robert Grant, a professor at the University of California, San Francisco, ...

Sequence of Shots May Lead to Effective HIV Vaccine, Mouse Study Finds

Posted 25 Jun 2015 by Drugs.com

THURSDAY, June 25, 2015 – It's unlikely that a single vaccine would ever enable the body to neutralize the HIV virus, but a sequence of immunizations might hold the key, a new mouse study suggests. The immune system could be guided in a series of steps to develop a special type of HIV-fighting antibody, a team of researchers said. Each immunization would be customized for specific stages of the ...

FDA Approves Prezcobix (darunavir and cobicistat) for HIV-1 Infection in Adults

Posted 29 Jan 2015 by Drugs.com

TITUSVILLE, N.J., Jan. 29, 2015 /PRNewswire/ – Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced the U.S. Food and Drug Administration (FDA) has approved Prezcobix (darunavir 800 mg/cobicistat 150 mg) tablets, an HIV-1 protease inhibitor combined with a CYP3A4 inhibitor, for the treatment of human immunodeficiency virus (HIV-1) in combination with other ...

FDA Approves Evotaz (atazanavir and cobicistat) for HIV-1 Infection in Adults

Posted 29 Jan 2015 by Drugs.com

PRINCETON, N.J. – January 29, 2015 --(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved Evotaz (atazanavir 300 mg and cobicistat 150 mg) tablets in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. Evotaz is coformulated to be one pill, once-daily, combining the protease ...

Ask a Question

Further Information

Related Condition Support Groups

HIV Infection

Related Drug Support Groups

Tybost

Cobicistat Patient Information at Drugs.com